Biomarkers for clinical outcome among patients with advanced or metastatic NSCLC treated with pembrolizumab alone or in combination with chemotherapy

被引：0
|
作者：
Abed, Afaf [1 ,2 ,3 ]
Beasley, Aaron [1 ,2 ]
Reid, Anna [1 ,2 ]
Law, Nc [4 ]
Leslie, Calapre [1 ,2 ]
Michael, Millward [3 ]
Johnny, Lo [1 ]
Elin, Gray [1 ,2 ]
机构：
[1] Edith Cowan Univ, Sch Sci, Joondalup, Australia
[2] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, Australia
[3] Univ Western Australia, Sch Med, Crawley, Australia
[4] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA, Australia
来源：
RESPIROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
34
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [21] ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC
    Shiqi Mao
    Fei Zhou
    Yiwei Liu
    Shuo Yang
    Bin Chen
    Jian Xu
    Fengying Wu
    Xuefei Li
    Chao Zhao
    Wanying Wang
    Qian Liu
    Xiaofei Yu
    Keyi Jia
    Chuchu Shao
    Caicun Zhou
    Guanghui Gao
    Shengxiang Ren
    Cancer Immunology, Immunotherapy, 2022, 71 : 219 - 228
  • [22] Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC
    Mok, T. S. K.
    Cappuzzo, F.
    Jotte, R. M.
    Reck, M.
    Papadimitrakopoulou, V.
    Sandler, A.
    Waterkamp, D.
    Verret, W.
    Shen, Y.
    Socinski, M. A.
    ANNALS OF ONCOLOGY, 2015, 26 : 106 - 106
  • [23] ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC
    Mao, Shiqi
    Zhou, Fei
    Liu, Yiwei
    Yang, Shuo
    Chen, Bin
    Xu, Jian
    Wu, Fengying
    Li, Xuefei
    Zhao, Chao
    Wang, Wanying
    Liu, Qian
    Yu, Xiaofei
    Jia, Keyi
    Shao, Chuchu
    Zhou, Caicun
    Gao, Guanghui
    Ren, Shengxiang
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (01) : 219 - 228
  • [24] Clinical Outcome of Neoadjuvant of Tislelizumab Plus Chemotherapy for Chinese Locally Advanced NSCLC Patients
    Wang, Y.
    Zhao, Q.
    Miao, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S581 - S581
  • [25] Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
    Wen, Miaomiao
    Xia, Jinghua
    Sun, Ying
    Wang, Xuejiao
    Fu, Xianghui
    Zhang, Yanning
    Zhang, Zhipei
    Zhou, Yongan
    Li, Xiaofei
    BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 183 - 190
  • [26] Impact of high fasting plasma glucose in the clinical outcome of patients with advanced NSCLC with PD-L1 ≥ 50% treated with frontline pembrolizumab
    Llop Serna, S.
    Puig, E.
    Palmero, R.
    Brenes, J.
    Vilarino, N.
    Ruffinelli, J. C. C.
    Mesia Barroso, C.
    Saldana Canada, J.
    Jove Casulleras, M.
    Brao Perez, I.
    Arellano, M.
    Luciano Mateo, F. N.
    Peiro Martinez, I.
    Munoz Pinedo, C.
    Nadal, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1012 - S1012
  • [27] Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
    Long, Yaping
    Xiong, Qi
    Song, Qi
    Li, Yao
    Li, Xiaoyan
    Qin, Boyu
    Huang, Ziwei
    Hu, Yi
    Yang, Bo
    THORACIC CANCER, 2022, 13 (03) : 394 - 403
  • [28] 3-Year Overall Survival for Patients with Advanced NSCLC Treated with Pembrolizumab
    Hellmann, Matthew D.
    Leighl, Natasha B.
    Hui, Rina
    Carcereny, Enric
    Felip, Enriqueta
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani S.
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew A.
    Ramalingam, Suresh S.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Piperdi, Bilal
    Garon, Edward B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 60 - 61
  • [29] Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)
    Jansen, Y.
    Rozeman, E. A.
    Hojberg, L.
    Foppen, M. Geukes
    Schreuer, M.
    van Thienen, J. V.
    Bastholt, L.
    Schmidt, H.
    Haanen, J. B. A. G.
    Svane, I. M.
    Arance Fernandez, A. M.
    Blank, C.
    Neyns, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001
    Ahn, M. -J.
    Gandhi, L.
    Hamid, O.
    Hellmann, M. D.
    Garon, E. B.
    Ramalingam, S. S.
    Lubiniecki, G. M.
    Zhang, J.
    Piperdi, B.
    Hui, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
12345